Our previous work demonstrating the efficacy of dual targeting of STAT3 and Ref‐1 was performed in pancreatic cancer cells, MIA‐PaCa‐2, Panc‐1, Panc10.05 and Pa03C using laboratory‐based STAT3 inhibitors, STATTIC and S31‐201.6 Here, STAT3 is linked to pancreatic neoplasm.